Aurora kinase-a expression heterogeneity and potential benefit of combination therapy in prostate adenocarcinoma

Aurora kinase-a expression heterogeneity and potential benefit of combination therapy in prostate adenocarcinoma

BackgroundAurora kinase A (AURKA) is aberrantly expressed in a large number of tumors and promotes tumor progression by regulating the cell cycle, chromosomal instability, and drug resistance. However, its heterogeneous expression and combination therapy benefit in prostate adenocarcinoma (PRAD) is...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ru Chen, Qianyi Qiu, Weiting Xie, Jun Lin, Rong Liu, Jianhui Chen, Shaoxing Zhu, Yiming Su
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Cell and Developmental Biology
Subjects:	AURKA heterogeneity prostate adenocarcinoma (PRAD) AURKA inhibitor combination therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fcell.2025.1608711/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Aurora kinases signaling in cancer: from molecular perception to targeted therapies
by: Prerna Vats, et al.
Published: (2025-06-01)

Combination of AURKA inhibitor and MEK inhibitor strongly enhances G1 arrest and induces synergistic antitumor effect on KRAS or BRAF mutant colon cancer cells
by: Masashi Sato, et al.
Published: (2025-09-01)

Interaction of AURKA with TRIM28 revives dormant LSCC cells via Akt signaling pathway to promote LSCC metastasis
by: Liyun Yang, et al.
Published: (2025-01-01)

Impact of ITH on PRAD patients and feasibility analysis of the positive correlation gene MYLK2 applied to PRAD treatment
by: Chuanyu Ma, et al.
Published: (2025-05-01)

Integrated bioinformatics analysis to explore potential therapeutic targets and drugs for small cell carcinoma of the esophagus
by: Maofei Zhu, et al.
Published: (2025-01-01)

Asynchronous replication of AURKA and TP53 genes in gastric cancer patients and patients with multiple tumors
by: V. V. Tsepenko, et al.
Published: (2019-07-01)

O6-methylguanine DNA methyltransferase (MGMT) expression in U1242 glioblastoma cells enhances in vitro clonogenicity, tumor implantation in vivo, and sensitivity to alisertib-carboplatin combination treatment
by: Müge Sak, et al.
Published: (2025-04-01)

Corrigendum: O6-methylguanine DNA methyltransferase (MGMT) expression in U1242 glioblastoma cells enhances in vitro clonogenicity, tumor implantation in vivo, and sensitivity to alisertib-carboplatin combination treatment
by: Müge Sak, et al.
Published: (2025-06-01)

Sanguinarine identified as a natural dual inhibitor of AURKA and CDK2 through network pharmacology and bioinformatics approaches
by: Xiang Li, et al.
Published: (2024-11-01)

Identification of Novel Molecular Panel as Potential Biomarkers of PAN-Gastrointestinal Cancer Screening: Bioinformatics and Experimental Analysis
by: Fatemeh Hajibabaie, et al.
Published: (2025-07-01)

Significance of LC3B autophagy marker in recurrent prostate adenocarcinoma
by: Elena S. Voronina, et al.
Published: (2022-03-01)

Morphological markers of secretory activity in prostatic adenocarcinoma
by: Janković-Veličković Ljubinka, et al.
Published: (2007-01-01)

Specific cell’s nuclei DNA content and cellular heterogeneity of colon adenocarcinoma
by: A. N. Grabovoy, et al.
Published: (2015-04-01)

The unraveling of a rare case of prostate adenocarcinoma presenting as orbital mass
by: Girish A. Kadkol, et al.
Published: (2025-04-01)

Mucin-producing urothelial-type adenocarcinoma of the prostate with a gene mutation characteristic of intestinal adenocarcinoma: case report and literature review
by: Ao Yu, et al.
Published: (2025-01-01)

Prostatic duct adenocarcinoma—A challenging variant of prostate cancer in a low‐resource setting
by: Ronald Okidi, et al.
Published: (2024-11-01)

Association of Perineural Invasion of Adenocarcinoma in Prostate Biopsy with Pathological and Clinical Outcomes
by: Rita Rueangrong, et al.
Published: (2025-08-01)

Intratumor heterogeneity related signature for clinical outcome and immunotherapy advantages in lung adenocarcinoma
by: Yanhua Zuo, et al.
Published: (2025-03-01)

The role of endothelial cell-related gene COL1A1 in prostate cancer diagnosis and immunotherapy: insights from machine learning and single-cell analysis
by: Gujun Cong, et al.
Published: (2025-01-01)

Tumor-to-Tumor Metastasis of Prostatic Adenocarcinoma in Transitional Meningioma: A Case Report and Literature Review
by: Rafael Harter Tomaszeski, et al.
Published: (2025-06-01)

Mucinous adenocarcinoma of the prostate with extremely low prostate-specific antigen levels, recurrent disease: a case report
by: Xu Yu, et al.
Published: (2025-08-01)

Expression of cytokeratin 19 in prostatic adenocarcinoma: a systematic review
by: Sina Shahshenas, et al.
Published: (2025-01-01)

DPH2 is a biomarker associated with cell death, immunity and prognosis based on pan-cancer analysis
by: Maolin Xiao, et al.
Published: (2025-02-01)

Characterizing PSMA heterogeneity in prostate cancer and identifying clinically actionable tumor associated antigens in PSMA negative cases
by: Yelin Mulati, et al.
Published: (2025-07-01)

Paraneoplastic cerebellar degeneration in a patient with anti-Yo antibodies and prostate adenocarcinoma
by: Ekaterina S. Koroleva, et al.
Published: (2017-10-01)

Dysadherin expression in prostatic adenocarcinoma and its relationship with E-cadherin and β-catenin
by: Rinë Limani, et al.
Published: (2025-12-01)

Synchronous mantle cell lymphoma and prostate adenocarcinoma-is it just a coincidence?
by: Petković Ivan, et al.
Published: (2016-01-01)

Oncological outcomes of patients with ductal adenocarcinoma of the prostate receiving radical prostatectomy or radiotherapy
by: Mengzhu Liu, et al.
Published: (2021-04-01)

Incidence of prostate adenocarcinoma in transurethral resection of the prostate patients
by: Yahia Ghazwani, et al.
Published: (2025-01-01)

Comprehensive analysis of the LINC01122/TPD52 axis as a predictive biomarker in prostate adenocarcinoma
by: Zhi Shang, et al.
Published: (2025-05-01)

Clonal divergence and genomic meltdown in prostatic pleomorphic giant cell adenocarcinoma
by: Xiaoshi Ma, et al.
Published: (2025-08-01)

Leveraging cell death patterns to predict metastasis in prostate adenocarcinoma and targeting PTGDS for tumor suppression
by: Bohong Chen, et al.
Published: (2024-09-01)

Solitary testicular metastasis post-prostatectomy for prostatic ductal adenocarcinoma: case report and literature review
by: Bo Chang, et al.
Published: (2025-02-01)

The expression and localization of estrogen receptor beta in hyperplastic and neoplastic prostate lesions
by: Fejsa-Levakov Aleksandra, et al.
Published: (2015-01-01)

Construction of machine learning models of lipid metabolism-related long non-coding RNA in lung adenocarcinoma is associated with microenvironmental heterogeneity and immunotherapy
by: Jiali Xiong, et al.
Published: (2024-10-01)

Epigenetic evolution and clinicopathological implications of distinct DNA methylation profiles in pancreatic ductal adenocarcinoma
by: Keiichiro Kitahama, et al.
Published: (2025-08-01)

Management of multiple primary prostate malignant tumors: case report of synchronous prostatic adenocarcinoma and lymphoma
by: Weihuang Zhuang, et al.
Published: (2025-06-01)

m6A regulator-mediated methylation modifications define the immune infiltration characteristics of the tumor microenvironment in prostate adenocarcinoma
by: Fajing Jia, et al.
Published: (2024-11-01)

Construction of a prostate adenocarcinoma molecular classification: integrating spatial transcriptomics with retrospective cohort validation
by: Bingnan Lu, et al.
Published: (2025-07-01)

Integrated single-cell RNA sequencing reveals the tumor heterogeneity and microenvironment landscape during liver metastasis in adenocarcinoma of esophagogastric junction
by: Junrui Xu, et al.
Published: (2025-01-01)